Publications CCFA 2014 Poster: Modulation of inflammatory and disease biomarkers following 4 week treatment with AVX-470, an oral anti-TNF antibody, in ulcerative colitis patients UEGW 2014 Presentation:AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in-Human Trial ACG 2014 Poster: Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of AVX-470, an Oral, Bovine-Derived Anti-TNF Antibody, in Patients with Active Ulcerative Colitis (UC): Initial Human Experience Bhol et. al, “AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease” Inflamm Bowel Dis 2013;19:2273–2281.
